Breaking: Boston Scientific to acquire Penumbra for ~$14.5B 2025 revenue $1.40B, up ~17.5% Founded 2004 in Alameda, California ~4,500 employees in ~100 markets Lightning Flash 3.0 - the next evolution in CAVT NYSE: PEN since 2015 Breaking: Boston Scientific to acquire Penumbra for ~$14.5B 2025 revenue $1.40B, up ~17.5% Founded 2004 in Alameda, California ~4,500 employees in ~100 markets Lightning Flash 3.0 - the next evolution in CAVT NYSE: PEN since 2015
YesPress Dossier · Medtech

Penumbra,
Inc.

A surgeon, a lawyer, and a single stubborn idea: get the clot out. Twenty-two years later, a $14.5 billion idea.

2004
Founded
$1.40B
2025 Revenue
~4,500
Employees
~100
Markets
Penumbra, Inc. logo - the Penumbra P mark
The P that races the clock. Penumbra's mark sits on devices threaded through the body's smallest vessels - Alameda, California.
The Scene

A Race Measured in Minutes

Somewhere right now, a clot has lodged in a vessel it has no business being in. A brain is going quiet. An emergency-room clock starts ticking, and every minute that passes is roughly two million neurons that will not be coming back. In a catheterization lab, a physician threads a tube thinner than a coffee stirrer up through the body, around bends a roadmap could never fully prepare you for, until it reaches the blockage. Then a machine begins to pull. The clot lets go. The brain comes back online.

That machine, and the catheter, and the algorithm deciding whether it is staring at a clot or just flowing blood - there is a good chance it says Penumbra on the side. This is a company that does not sell software you forget you signed up for. It sells the minutes back.

Field note: the "penumbra" is the brain tissue around a stroke that is injured but not yet dead. The company named itself after the deadline.
$14.5B
Boston Scientific deal value (Jan 2026)
$374
Per-share acquisition price
$30
2015 IPO price per share
100%
Focus: getting the clot out
The Origin

A Lawyer and His Best Friend From College

Most medical device companies are founded by engineers. Penumbra was co-founded by a lawyer. Adam Elsesser was a partner at a San Francisco law firm before he traded the courtroom for the operating room, first running a neuro-intervention startup that Boston Scientific bought, then - in June 2004 - starting Penumbra with Dr. Arani Bose, a neuro-interventional surgeon and, conveniently, his best friend from college.

Bose became the company's chief innovator: the man who had seen, up close, what a clot does on a deadline. Elsesser became the CEO who has not let go of the wheel since - President since 2015, Chairman too. It is an unusual pairing that turned out to be exactly the right one: the clinician who knew the problem cold, and the operator who knew how to build a company around it.

"Penumbra's commitment to saving lives is chief among its values."

The premise was almost rude in its simplicity. Stroke treatment, at the time, leaned heavily on drugs that dissolve clots over time - time being the one thing a stroke patient does not have. Penumbra bet on the opposite: go in and physically remove the thing. Aspiration. Suction. Pull it out.

The Toolkit

What They Actually Make

Penumbra builds interventional devices for vascular and neuro therapies - the catheters, coils, pumps, and clot-retrievers that physicians steer through the body's plumbing. Here is the working kit.

Neuro / Stroke

Penumbra System

Aspiration-based reperfusion catheters and separators for revascularizing patients with acute ischemic stroke caused by large-vessel occlusion. The original idea, refined for two decades.

Peripheral / Venous

Indigo System with Lightning

Computer Assisted Vacuum Thrombectomy - "CAVT" - that removes clots from peripheral arteries and veins using intelligent aspiration rather than brute force.

Pulmonary & Venous

Lightning Flash 3.0

The latest CAVT generation, built to clear pulmonary and venous thrombus fast. Its algorithm is tuned to tell the difference between a clot and your own flowing blood.

Neurovascular

THUNDERBOLT & Coils

Mechanical thrombectomy plus embolization and detachable coil systems used to treat aneurysms and occlude vessels in the brain.

Rehabilitation

REAL Immersive System

The plot twist: virtual reality for healthcare. REAL y-Series for clinical rehab, REAL i-Series for wellness and mental health. Patients put on a headset to relearn movement.

Access

Catheters & Aspiration Engine

The vascular access catheters and the pump that powers the whole thrombectomy act - the unglamorous parts that make the dramatic part possible.

Detail worth noticing: Lightning systems are the only computer-assisted mechanical thrombectomy devices cleared in the U.S.
The Trajectory

From IPO Curiosity to $1.4 Billion

Penumbra went public on the NYSE in 2015 in one of medtech's larger IPOs of that year, pricing at $30 a share and raising roughly $125 million net. A decade later, the revenue line tells the rest of the story.

Approximate Annual Revenue

Public-source estimates · USD
2015
~$0.19B
2018
~$0.45B
2021
~$0.76B
2024
~$1.19B
2025
$1.40B

Full-year 2025 landed at $1.40 billion, up roughly 17.5% over the prior year. Numbers like that are how a $30 share becomes a $374 one.

The Headline

The $14.5 Billion Homecoming

In January 2026, Boston Scientific announced a definitive agreement to acquire Penumbra in a cash-and-stock deal valuing the company at about $14.5 billion - $374 per share. There is a quiet symmetry to it: Boston Scientific is the same company that, years earlier, bought the neuro-intervention startup Adam Elsesser ran before Penumbra existed. The deal gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular care, two adjacencies it has wanted. It is expected to close in 2026.

"Lightning products are the only computer-aided mechanical thrombectomy systems currently available in the U.S."

- On the technology that anchored the deal
The Record

Milestones

2004

Founded in Alameda

Adam Elsesser and Dr. Arani Bose start Penumbra with a bet on physically removing clots.

2015

IPO on the NYSE

Prices at $30/share, raising ~$125M net in one of medtech's biggest IPOs of the year. Ticker: PEN.

2022

VR Goes Clinical

Expands the REAL Immersive System with next-gen y-Series, including hands-free, full-body rehabilitation.

2025

Lightning Flash 3.0

Launches the next evolution of Computer Assisted Vacuum Thrombectomy for pulmonary and venous thrombus.

Jan 2026

The $14.5B Agreement

Boston Scientific announces a deal to acquire Penumbra at $374/share. 2025 revenue confirmed at ~$1.40B.

For The Reader

Who This Is For

Stroke & Vascular Teams

Interventional neurologists, radiologists, and vascular surgeons use Penumbra's catheters and CAVT systems to remove clots in stroke, PE, and peripheral disease.

Hospitals & Stroke Centers

Comprehensive stroke centers across ~100 markets stock the Penumbra and Indigo systems as front-line clot-removal tools.

Rehab & Mental Health

Providers - including the Veterans Health Administration - use the REAL System's VR to support rehabilitation and wellness.

The Margins

Things That Stick

Watch

Interviews & Demos

► YouTube

Penumbra Official Channel

 ► Product Demo

Lightning Flash & Indigo System

 ► Interview

Adam Elsesser, CEO
The Index

Where To Find Them

Websitepenumbrainc.com LinkedIn/company/penumbra-inc X / Twitter@penumbrainc Facebook/penumbraincmedtech YouTubePenumbra Inc NewsFY2025 Results NewsBoston Scientific Deal ReferenceWikipedia
The Scene, Revisited

Back to the Clock

Return to that catheterization lab. The clot lets go, and the brain comes back online - but notice what has quietly changed in the room. The clock still runs, but it no longer runs alone. There is a machine deciding, in real time, whether it is pulling a clot or just blood. There is a catheter that reached a place a catheter had no business reaching. There is, two decades after a lawyer and his college roommate decided drugs-and-wait was not good enough, an entire vocabulary of getting the thing out.

Penumbra did not invent the emergency. It changed what happens during it. And in 2026, that change is worth about $14.5 billion - which is one way to measure it. The other way is the patient who walks out of the hospital, slightly annoyed they missed lunch, with no idea their afternoon was a race they very nearly lost.

It does not sell software you forget you signed up for. It sells the minutes back.